Health Canada approves Lundbeck's Vyepti (eptinezumab)--the first and only intravenous preventive treatment for migraine


12 January 2021 - Lundbeck is pleased to announce that Vyepti (eptinezumab) has been approved by Health Canada for the preventive treatment of migraine in adults who have at least 4 migraine days per month.

The efficacy and safety of Vyepti was demonstrated in two Phase 3 clinical trials (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine, which also included patients with a dual diagnosis of chronic migraine and medication overuse headache).

Read Lundbeck press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada